La vendita allo scoperto per TransCode Therapeutics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di TransCode Therapeutics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

TransCode Therapeutics (NASDAQ:RNAZ) Azioni, Report sulle vendite allo scoperto

TRANSCODE THERAPEUTICS INC

TransCode Therapeutics

TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.

New,York,Ny - usa-may,5,,2015,Packages,Of,Tyson,Brand,Chicken

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

HSIC

RNAZ

Wall Street guarda ai report trimestrali di importanti aziende come Tyson Foods e Cummins. Scopri i dettagli.

Tyson Foods, Ford e altre 3 azioni da tenere d&#39;occhio in questo lunedì

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics Inc

WIIM

HOWL

Werewolf Therapeutics shares are trading higher after the company announced a patient with advanced skin cancer has been in remission after enrolling in the investigational novel conditionally activated IL-2 pro-drug WTX-124.

<p>Currenc Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.04) by 225 percent. This is a 44.44 percent decrease over losses of $(0.09) per share from the same period last year.  The company reported quarterly sales of $10.06 million which missed the analyst consensus estimate of $10.50 million by 4.23 percent.  This is a 23.26 percent decrease over sales of $13.10 million the same period last year.</p>


Earnings Misses

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

Currenc Group Q1 EPS $(0.13) Misses $(0.04) Estimate, Sales $10.06M Miss $10.50M Estimate

TTWO

Take-Two Interactive shares are trading lower after the company announced a proposed public offering of common stock.

<p>Take-Two Interactive Software, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) (the "Company" or "Take-Two") today announced a proposed underwritten public offering of $1 billion of shares of its common stock. All shares to be sold in the offering are to be sold by the Company. In addition, the Company expects to grant the underwriters a 30-day option to purchase up to an additional $150 million of shares of its common stock. Take-Two intends to use the net proceeds for general corporate purposes, which may include the repayment of outstanding debt and future acquisitions. The offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering will be completed, or the actual size or terms of the offering.</p>
<p>J.P. Morgan Securities LLC and Goldman Sachs &amp; C</p>


Offerings

Take-Two Interactive Software Announces Proposed Public Offering Of $1B Of Common Stock

Biotech

General

ORKA

Oruka Therapeutics Initiates Dosing Of Healthy Volunteers In Its First Clinical Trial Of ORKA-002, The Company's Novel, Subcutaneously Administered, Half-life Extended Monoclonal Antibody Targeting IL-17A And IL-17F

<p><i>There are nearly 40,000 U.S. cases of cutaneous squamous cell carcinoma each year that advance to stages that are difficult to treat and life-threatening</i></p>
<p><i>Skin Cancer Awareness Month in May shines a spotlight on the growing burden of advanced skin cancers</i></p>
<p><i>The investigational drug is designed to be activated in the tumor microenvironment, including in cutaneous squamous cell carcinoma</i></p>
<p>&nbsp;</p>


Patient With Advanced Skin Cancer In Remission Over Year After Clinical Trial Of Werewolf Therapeutics' investigational Novel Conditionally Activated IL-2 pro-Drug WTX-124

<p>Rafael Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RFL#NYSE">RFL</a>, NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RFL#NYSE">RFL</a>) today provided an update to the subscription rights related to its Public Warrants in connection with its previously announced rights offering.</p>
<p>Under the rights offering, Rafael Holdings has distributed one (1) non-transferable subscription right for each share of Class B common stock or Class A common stock, or for each share of Class B common stock issuable upon exercise of the outstanding warrants, initially issued on May 11, 2020 by Cyclo Therapeutics, Inc. (the "Public Warrants"), in each case, held as of May 9, 2025, the record date for the rights offering.</p>
<p>Each subscription right will entitle the Holder of a share of Class A common stock or Class B common stock to purchase 0.603 of a share of Class B common stock at a subscription price of $1.28 per share.</p>
<p>Each Holder of a Public Warrant received 0.3525 of a subscription right (corresponding to the ratio between Public Warrants and the portion of a share of Class B common stock for which each is exercisable). Accordingly, a holder of three (3) Public Warrants received a full subscription right. Each full subscription right entitles the Holder to purchase 0.603 of a share of Class B common stock at a subscription price of $1.28 per share.</p>
<p>Subscription rights may only be exercised in whole numbers, and fractional shares will not be issued. The number of shares that may be purchased by each holder of subscription rights will be rounded down to the nearest whole number.</p>
<p>All terms of the rights offering remain unchanged.</p>


Rafael Holdings Updates Terms Of Rights Offering, Granting 1 Non-Transferable Subscription Right Per Share Or Equivalent Public Warrant Held As Of May 9, 2025, Allowing Holders To Purchase 0.603 Shares Of Class B Common Stock At $1.28 Per Share, With Public Warrant Holders Receiving 0.3525 Rights Per Warrant And Full Rights Granted Per 3 Warrants Held

<p>Paramount Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGRE#NYSE">PGRE</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $5.38, a high estimate of $8.00, and a low estimate of $4.00. Surpassing the previous average price target of $4.94, the current average has increased by 8.91%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747771299_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Paramount Group. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$8.00</td>
<td>$4.50</td>
</tr>
<tr>
<td>Blaine Heck</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$4.50</td>
<td>$5.00</td>
</tr>
<tr>
<td>Ronald Kamdem</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$4.00</td>
<td>$4.25</td>
</tr>
<tr>
<td>Vikram Malhotra</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$5.00</td>
<td>$6.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Paramount Group. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Paramount Group compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Paramount Group's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Paramount Group's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PGRE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Paramount Group analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Get to Know Paramount Group Better</h2>
<p>Paramount Group Inc is a real estate investment trust engaged in owning, operating, managing, acquiring, and redeveloping high-quality, Class A office properties in select central business district (CBD) submarkets of New York City and San Francisco. The company operates in two geographical segments New York and San Francisco. The company derives nearly all of its majority of revenue from rental income.</p>
<h3>Paramount Group: A Financial Overview</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Paramount Group's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately <strong>-0.98%</strong> in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> Paramount Group's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-5.36%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Paramount Group's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-0.32%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Paramount Group's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>-0.13%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Paramount Group's debt-to-equity ratio is below the industry average. With a ratio of <b>1.19</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

PGRE

The Analyst Verdict: Paramount Group In The Eyes Of 4 Experts

<p>Across the recent three months, 8 analysts have shared their insights on Sun Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUI#NYSE">SUI</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Sun Communities, presenting an average target of $139.0, a high estimate of $150.00, and a low estimate of $126.00. A 0.1% drop is evident in the current average compared to the previous average price target of $139.14. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747771275_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Sun Communities by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aaron Hecht</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Joshua Dennerlein</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$132.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>Wesley Golladay</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$126.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Brad Heffern</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$147.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Aaron Hecht</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$140.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Anthony Hau</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$135.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Peter Abramowitz</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$150.00</td>
<td>-</td>
</tr>
<tr>
<td>Anthony Hau</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$142.00</td>
<td>$136.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sun Communities. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sun Communities compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Sun Communities's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Sun Communities's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SUI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Sun Communities analyst ratings.</strong></a></p>
<h2>Delving into Sun Communities's Background</h2>
<p>Sun Communities is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently owns a portfolio of 645 properties, which includes 341 manufactured housing communities, 166 residential vehicle communities, and 138 marina properties. Sun targets owning properties that are desirable as second homes or vacation properties with nearly 50% of the portfolio located in either Florida or Michigan near major bodies of water.</p>
<h3>A Deep Dive into Sun Communities's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Revenue Growth:</strong> Sun Communities displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately <strong>0.24%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-9.19%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Sun Communities's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-0.61%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Sun Communities's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-0.26%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.06</strong>.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Assessing Sun Communities: Insights From 8 Financial Analysts

<ul>
<li><i>VACCO provides highly engineered mission-critical components and subsystems to the space and naval defense channels</i></li>
<li><i>Customers and partners expected to benefit from the combined design, engineering and manufacturing expertise and broader integrated capabilities of both companies</i></li>
<li><i>Expands product breadth and capacity in two of RBC's fastest growing channel</i></li>
</ul>


RBC Bearings To Acquire VACCO Industries From ESCO Technologies For $310M

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Citigroup</strong>.</p>
<p>Looking at options history for Citigroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) we detected 17 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 47% of the investors opened trades with bullish expectations and 41% with bearish.</p>
<p>From the overall spotted trades, 8 are puts, for a total amount of $1,324,770 and 9, calls, for a total amount of $1,272,850.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $50.0 to $85.0 for Citigroup over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Citigroup's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Citigroup's whale trades within a strike price range from $50.0 to $85.0 in the last 30 days. </p>
<h3>Citigroup Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747771258_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$27.4</td>
<td>$27.15</td>
<td>$27.26</td>
<td>$50.00</td>
<td>$545.2K</td>
<td>6.4K</td>
<td>202</td>
</tr>
<tr>
<td>C</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$9.1</td>
<td>$9.0</td>
<td>$9.0</td>
<td>$85.00</td>
<td>$450.0K</td>
<td>430</td>
<td>1.0K</td>
</tr>
<tr>
<td>C</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$1.88</td>
<td>$1.85</td>
<td>$1.85</td>
<td>$67.50</td>
<td>$347.6K</td>
<td>8.1K</td>
<td>2.3K</td>
</tr>
<tr>
<td>C</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/17/27</td>
<td>$4.75</td>
<td>$4.25</td>
<td>$4.5</td>
<td>$57.50</td>
<td>$337.5K</td>
<td>527</td>
<td>750</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/17/26</td>
<td>$8.0</td>
<td>$7.95</td>
<td>$7.95</td>
<td>$80.00</td>
<td>$261.5K</td>
<td>9.6K</td>
<td>528</td>
</tr>
</tbody>
</table>
</p>
<h3>About Citigroup</h3>
<p>Citigroup is a global financial-services company doing business in more than 100 countries and jurisdictions. Citigroup's operations are organized into five primary segments: services, markets, banking, US personal banking, and wealth management. The bank's primary services include cross-border banking needs for multinational corporates, investment banking and trading, and credit card services in the United States.</p>
<p>Following our analysis of the options activities associated with Citigroup, we pivot to a closer look at the company's own performance.</p>
<h3>Citigroup's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 6,197,275, the C's price is down by -0.42%, now at $75.81. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 52 days.</li>
</ul>
<h3>What Analysts Are Saying About Citigroup</h3>
<p>Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $94.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Oppenheimer has decided to maintain their Outperform rating on Citigroup, which currently sits at a price target of $94. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Citigroup, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Citigroup Unusual Options Activity

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Merck &amp; Co</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MRK, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 33 uncommon options trades for Merck &amp; Co.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 42% bullish and 33%, bearish.</p>
<p>Out of all of the special options we uncovered, 9 are puts, for a total amount of $753,544, and 24 are calls, for a total amount of $1,133,972.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $65.0 to $100.0 for Merck &amp; Co over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Merck &amp; Co's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Merck &amp; Co's whale activity within a strike price range from $65.0 to $100.0 in the last 30 days. </p>
<h3>Merck &amp; Co Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747771253_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$7.2</td>
<td>$7.05</td>
<td>$7.05</td>
<td>$70.00</td>
<td>$352.5K</td>
<td>811</td>
<td align="right">501</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$9.15</td>
<td>$9.05</td>
<td>$9.05</td>
<td>$80.00</td>
<td>$135.7K</td>
<td>2.3K</td>
<td align="right">259</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/17/27</td>
<td>$27.3</td>
<td>$26.5</td>
<td>$27.04</td>
<td>$100.00</td>
<td>$108.1K</td>
<td>116</td>
<td align="right">41</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/23/25</td>
<td>$2.79</td>
<td>$2.71</td>
<td>$2.79</td>
<td>$76.00</td>
<td>$97.6K</td>
<td>1.0K</td>
<td align="right">399</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$10.0</td>
<td>$9.9</td>
<td>$9.95</td>
<td>$80.00</td>
<td>$89.5K</td>
<td>2.0K</td>
<td align="right">216</td>
</tr>
</tbody>
</table>
</p>
<h3>About Merck &amp; Co</h3>
<p>Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.</p>
<h3>Present Market Standing of Merck &amp; Co</h3>
<ul>
<li>With a volume of 10,575,757, the price of MRK is up 0.86% at $77.89. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 70 days.</li>
</ul>
<h3>What Analysts Are Saying About Merck &amp; Co</h3>
<p>Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $84.5.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Neutral, setting a price target of $85.<br />
&#x2A; Reflecting concerns, an analyst from Citigroup lowers its rating to Neutral with a new price target of $84.</p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Merck &amp; Co, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Spotlight on Merck & Co: Analyzing the Surge in Options Activity

<p>Benzinga's options scanner just detected over 19 options trades for <strong>Sunrun</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) summing a total amount of $1,115,850.</p>
<p>At the same time, our algo caught 3 for a total amount of 224,850.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $8.0 to $25.0 for Sunrun during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Sunrun's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Sunrun's substantial trades, within a strike price spectrum from $8.0 to $25.0 over the preceding 30 days.</p>
<h3>Sunrun Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747771248_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>RUN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$1.7</td>
<td>$1.63</td>
<td>$1.7</td>
<td>$11.00</td>
<td>$170.0K</td>
<td>92.0K</td>
<td>1.7K</td>
</tr>
<tr>
<td>RUN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$0.44</td>
<td>$0.2</td>
<td>$0.4</td>
<td>$9.50</td>
<td>$108.0K</td>
<td>18</td>
<td>2.7K</td>
</tr>
<tr>
<td>RUN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$1.25</td>
<td>$1.12</td>
<td>$1.21</td>
<td>$15.00</td>
<td>$103.8K</td>
<td>43.0K</td>
<td>9.4K</td>
</tr>
<tr>
<td>RUN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$1.17</td>
<td>$0.81</td>
<td>$1.0</td>
<td>$15.00</td>
<td>$103.7K</td>
<td>43.0K</td>
<td>1.0K</td>
</tr>
<tr>
<td>RUN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$1.0</td>
<td>$0.89</td>
<td>$1.0</td>
<td>$15.00</td>
<td>$102.5K</td>
<td>43.0K</td>
<td>2.5K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Sunrun</h3>
<p>Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed either by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.</p>
<p>Following our analysis of the options activities associated with Sunrun, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is Sunrun Standing Right Now?</h3>
<ul>
<li>With a trading volume of 8,831,274, the price of RUN is down by 0.0%, reaching $11.29.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 77 days from now.</li>
</ul>
<h3>What The Experts Say On Sunrun</h3>
<p>A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $13.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from RBC Capital has decided to maintain their Outperform rating on Sunrun, which currently sits at a price target of $12.<br />
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on Sunrun with a target price of $15. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Sunrun, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Smart Money Is Betting Big In RUN Options

<p>4 analysts have expressed a variety of opinions on Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $3.25, a high estimate of $5.00, and a low estimate of $2.00. This current average has decreased by 43.48% from the previous average price target of $5.75. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747771245_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>A clear picture of Macrogenics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mayank Mamtani</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$3.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$5.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Peter Lawson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$3.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$2.00</td>
<td>$4.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Macrogenics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Macrogenics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Macrogenics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Macrogenics's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MGNX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Macrogenics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Get to Know Macrogenics Better</h2>
<p>Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.</p>
<h3>Macrogenics: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Macrogenics's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately <strong>44.9%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-311.07%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Macrogenics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-42.05%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Macrogenics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-16.88%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Macrogenics's debt-to-equity ratio surpasses industry norms, standing at <strong>0.47</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


MGNX

4 Analysts Assess Macrogenics: What You Need To Know

<p>AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) has outperformed the market over the past 10 years by 2.01% on an annualized basis producing an average annual return of 12.89%. Currently, AECOM has a market capitalization of $14.41 billion. </p>
<p><strong>Buying $1000 In ACM:</strong> If an investor had bought $1000 of ACM stock 10 years ago, it would be worth <strong>$3,362.09</strong> today based on a price of $108.93 for ACM at the time of writing.</p>
<h3>AECOM's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747771241_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today

<p><a href="https://www.bloomberg.com/news/articles/2025-05-20/uber-squeezes-more-from-aurora-stake-with-1-2-billion-bond-sale?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-20/uber-squeezes-more-from-aurora-stake-with-1-2-billion-bond-sale?embedded-checkout=true</a></p>


UBER

'Uber Squeezes More From Aurora Stake With $1.2 Billion Bond Sale'- Bloomberg

<p><strong>Welltower's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) short percent of float has risen 39.88% since its last report. The company recently reported that it has <strong>11.86 million shares sold short</strong>, which is 2.35% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 4.5 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Welltower Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747771233_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Welltower has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Welltower's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Welltower's peer group average for short interest as a percentage of float is 6.66%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

WELL

Looking Into Welltower's Recent Short Interest

<p>In the last three months, 7 analysts have published ratings on Enterprise Prods Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPD#NYSE">EPD</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $36.57, with a high estimate of $38.00 and a low estimate of $35.00. Witnessing a positive shift, the current average has risen by 1.58% from the previous average price target of $36.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747771230_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>A clear picture of Enterprise Prods Partners's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Theresa Chen</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$36.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Spiro Dounis</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$35.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Jeremy Tonet</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$38.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Elvira Scotto</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$37.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Theresa Chen</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$37.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Robert Kad</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$38.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Holly Stewart</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$35.00</td>
<td>$33.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Enterprise Prods Partners. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Enterprise Prods Partners compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Enterprise Prods Partners's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Enterprise Prods Partners's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EPD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Enterprise Prods Partners analyst ratings.</strong></a></p>
<h2>Delving into Enterprise Prods Partners's Background</h2>
<p>Enterprise Products Partners is a master limited partnership that transports and processes natural gas, natural gas liquids, crude oil, refined products, and petrochemicals. It is one of the largest midstream companies, with operations servicing most producing regions in the continental US. Enterprise is particularly dominant in the NGL market and is one of the few MLPs that provide midstream services across the full hydrocarbon value chain.</p>
<h3>Financial Insights: Enterprise Prods Partners</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Revenue Growth:</strong> Over the 3M period, Enterprise Prods Partners showcased positive performance, achieving a revenue growth rate of <strong>4.45%</strong> as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Energy sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Enterprise Prods Partners's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>8.95%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>4.79%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Enterprise Prods Partners's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.81%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>1.09</strong>, Enterprise Prods Partners adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Enterprise Prods Partners Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)

<p><strong>Liberty Energy's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LBRT#NYSE">LBRT</a>) short percent of float has fallen 14.5% since its last report. The company recently reported that it has <strong>8.36 million shares sold short</strong>, which is 7.43% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.56 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Liberty Energy Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747771228_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Liberty Energy has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Liberty Energy's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Liberty Energy's peer group average for short interest as a percentage of float is 9.42%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


LBRT

Is the Market Bullish or Bearish on Liberty Energy?

<p><strong>Tesla Inc </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) plans to launch its robotaxis in Austin, Texas in June, according <a href="https://www.benzinga.com/topic/elon-musk">to CEO <strong>Elon Musk</strong></a>.</p>
<p><strong>What To Know</strong>: Musk, in an interview aired on Tuesday&#8217;s edition of CNBC&#8217;s &#8220;Power Lunch,&#8221; explained that the robotaxi rollout will start small and ramp up to hundreds of thousands of vehicles as soon as next year.</p>
<p>&#8220;We want to be very careful with the first introduction of unsupervised full self-driving, meaning the car&#8217;s driving around with no one in it,&#8221; Musk said.</p>
<p>Musk expects about 10 vehicles on the roads in the first week, about 1,000 driverless vehicles on the roads within a few months, and hundreds of thousands of vehicles capable of unsupervised full self-driving on the roads by the end of next year, &#8220;if not over a million.&#8221;</p>
<p>When CNBC&#8217;s <strong>David Faber</strong> asked why Musk is so confident, the CEO said Tesla vehicles are already driving themselves 24/7 with drivers in them, and the company has seen &#8220;essentially no interventions.&#8221;</p>
<p>Musk said that the company expects to unveil a business model for full self-driving similar to <strong>Uber Technologies Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) and <strong>Airbnb Inc </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>), where Tesla owners can rent out their vehicles when they aren&#8217;t using them.</p>
<p>&#8220;It&#8217;s a way for Tesla owners to earn revenue. Instead of having your car sit in the parking lot, your car could be earning money,&#8221; Musk said. &#8220;These things happen slowly, but then all at once.&#8221;</p>
<p><strong>See Also: <a href="https://www.benzinga.com/markets/25/05/45516240/tesla-cfo-vaibhav-taneja-receives-record-139-million-pay-surpassing-most-ceos-even-as-elon-musk-faces-compensation-lawsuit">Tesla CFO Vaibhav Taneja Receives Record $139 Million Pay, Surpassing Most CEOs</a></strong></p>
<p><strong>Why It Matters:</strong> Tesla bears have raised concerns about the company&#8217;s first-quarter performance, pointing to a&nbsp;9% year-over-year decrease in sales as automotive revenue dropped 20%. </p>
<p>Musk also told CNBC that the company has seen a &#8220;major rebound in demand&#8221; since the first quarter.</p>
<p>Production numbers were also well below those of the same period last year, but shares moved higher following the report as Musk announced plans to reduce time spent working on government initiatives and provided optimistic commentary around full self-driving and the company&#8217;s humanoid Optimus bots. Musk reiterated that vision on Tuesday.</p>
<p>&#8220;Really the only things that matter long term are autonomy and Optimus. Those overwhelmingly dominate the future financial success of the company,&#8221; Musk said.</p>
<p>Tesla has not provided an exact date for its robotaxi launch in Austin. </p>
<p>Musk's visionary rhetoric is often scrutinized due to <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36039263/did-tesla-overpromise-and-underdeliver-with-the-cybertruck">overpromising and underdelivering</a> on ambitious projects, especially regarding Tesla robotaxis.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">This is why it's possible for Tesla to have a million robotaxis by end of 2020 if we upgrade existing HW2 fleet of ~500k &amp; make at least ~500k FSD cars</p>
<p>&mdash; Kekius Maximus (@elonmusk) <a href="https://twitter.com/elonmusk/status/1148070210412265473?ref_src=twsrc%5Etfw">July 8, 2019</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p><strong>TSLA Price Action: </strong>Tesla shares were well off their highs for the session, but still up about 0.45% at $343.58 at the time of publication Tuesday. Tesla&#8217;s stock has gained approximately 44% over the past month, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.</p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45520017/why-morgan-stanley-remains-bullish-on-tesla"><strong>Why Morgan Stanley Remains Bullish On Tesla</strong></a></li>
<li><a href="https://www.benzinga.com/news/25/05/45519469/tesla-stock-rises-after-musk-reaffirms-leadership-and-business-rebound"><strong>Tesla Stock Rises After Musk Reaffirms Leadership And Business Rebound</strong></a></li>
</ul>
<p><em>Photo: courtesy of Tesla.</em></p>



Tech

ABNB

TSLA

Elon Musk Expects Tesla Robotaxi Launch For June: 'These Things Happen Slowly, Then All At Once'

Press Releases

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

Emerging Tech Quartet – PRSO, LXRX, PRTG, RNAZ – Drive Breakthroughs Across Defense, Obesity, Oncology, and RNA Therapeutics

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

Comments

TransCode Therapeutics

Vendite allo scoperto

TransCode Therapeutics (NASDAQ:RNAZ) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO